boehringer ingelheim glp-1 π¨ Survodutide, a weekly subcutaneous dual GLP-1/glucagon agonist, posts new top-line Phase 3 results today π SYNCHRONIZE-1: Adults with overweight/obesity randomized to survodutide vs. placebo for 76 weeks βοΈ 16.6% weight loss ( What is the pipeline for
Pay in 4 interest-free payments of $6.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Nov 20 - Nov 25

























